A5043639575- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Epigenetics and DNA Methylation
- Immune cells in cancer
- Urinary and Genital Oncology Studies
- Eosinophilic Esophagitis
- IL-33, ST2, and ILC Pathways
- Urinary Tract Infections Management
- Immunotherapy and Immune Responses
- Cancer-related gene regulation
- Helicobacter pylori-related gastroenterology studies
- Gut microbiota and health
- RNA modifications and cancer
- Dietary Effects on Health
- Genomics, phytochemicals, and oxidative stress
- Chemokine receptors and signaling
- Mindfulness and Compassion Interventions
- Immune responses and vaccinations
- CAR-T cell therapy research
- FOXO transcription factor regulation
- Urological Disorders and Treatments
- Phytoestrogen effects and research
- NF-κB Signaling Pathways
- Herbal Medicine Research Studies
The University of Texas Health Science Center at Houston
2015-2025
Urology San Antonio
2017-2025
The University of Texas Health Science Center at San Antonio
2015-2024
The University of Texas at San Antonio
2022-2023
The University of Texas MD Anderson Cancer Center
2019-2023
Mays Cancer Center at UT Health San Antonio
2021-2023
Audie L. Murphy Memorial VA Hospital
2018
// Neelam Mukherjee 1 , Niannian Ji Vincent Hurez 2 Tyler J. Curiel Maureen O. Montgomery Andrew Braun Marlo Nicolas 3 Marcela Aguilera 5 Dharam Kaushik Qianqian Liu 4 Jianhua Ruan Kerri A. Kendrick and Robert S. Svatek Department of Urology, University Texas Health San Antonio (UTHSA), Antonio, United States Medicine, Pathology, Epidemiology & Biostatistics, Computer Science, (UTSA), Correspondence to: email: svatek@uthscsa.edu Keywords: bladder cancer; NK cells; tumor-infiltrating...
Abstract Background Diagnosis and treatment of prostate cancer is associated with anxiety, fear, depression in up to one-third men. Yoga improves health-related quality life (QoL) patients several types cancer, but evidence its efficacy enhancing QoL lacking cancer. Methods In this randomized controlled study, 29 men newly diagnosed localized were yoga for 6 weeks ( n = 14) or standard-of-care 15) before radical prostatectomy. The primary outcome was self-reported QoL, assessed by the...
Background: Intravesical bacillus Calmette-Guérin (BCG) is the gold standard immunologic agent for treating patients with high-grade non-muscle invasive bladder cancer (NMIBC). Nevertheless, relapse rates remain high and BCG unresponsive NMIBC often requires removal. Preclinical data suggest that priming percutaneous vaccine could improve response to intravesical BCG.Methods: A single-arm trial (NCT02326168) was performed study safety, immunogenicity, preliminary efficacy of priming....
Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances vaccine efficacy against tuberculosis and killing capacity γδ T cells, which are critical for BCG's antitumor effects. Here, we monitored immunity, safety, tolerability combined with in patients NMIBC.A randomized double-blind trial oral (0.5 or 2.0 mg daily) versus placebo 1 month was conducted NMIBC...
// Neelam Mukherjee 1 , Eduardo Cardenas Roble Bedolla Rita Ghosh 1, 2, 3, 4 Departments of Urology, School Medicine, University Texas Health Science Center at San Antonio, TX 78229, USA 2 Pharmacology, 3 Molecular Medicine and Cancer Therapy Research Center, Correspondence to: Ghosh, email: ghoshr@uthscsa.edu Keywords: SETD6, methyltransferase, NF-κB, bladder cancer, signaling Received: September 01, 2016 Accepted: January 10,...
Abstract The mechanistic target of rapamycin (mTOR) integrates environmental inputs to regulate cellular growth and metabolism in tumors. However, mTOR also regulates T-cell differentiation activation, rendering applications inhibitors toward treating cancer complex. Preclinical data support distinct biphasic effects rapamycin, with higher doses directly suppressing tumor cell lower enhancing immunity. To address the translational relevance these findings, complex 1 (mTORC1) inhibitor, on T...
Anti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but effective in <30% of patients. Interleukin (IL)-2/αIL-2 complexes (IL-2c) that preferentially target IL-2 receptor β (CD122) augment CD8
Abstract Bacillus Calmette-Guérin (BCG) is the most effective intravesical agent at reducing recurrence for patients with high-grade, non–muscle-invasive bladder cancer. Nevertheless, response to BCG variable and strategies boost efficacy have not materialized. Prior work demonstrated a requirement either conventional αβ or nonconventional γδ T cells in mediating treatment efficacy, yet importance of T-cell antigen specificity BCG's effect unclear. Here, we provide direct evidence show that...
Checkpoint inhibitors offer promise in treating muscle-invasive and metastatic bladder cancer, but the optimal timing of their administration—neoadjuvant or adjuvant—remains unclear. To determine efficacy combining checkpoint inhibition with standard cisplatin-based chemotherapy, we conducted a phase II trial neoadjuvant anti-PD-1 (αPD-1) anti-CTLA-4 (αCTLA-4), combination cisplatin-gemcitabine, for patients cancer prior to radical cystectomy. In addition, novel murine model spontaneous was...
Abstract Background Bladder tumor‐infiltrating CD56 bright NK cells are more tumor cytotoxic than their dim counterparts. Identification of cell subsets is labor‐intensive and has limited utility in the clinical setting. Here, we sought to identify a surrogate marker bladder test its prognostic significance. Methods were characterized with multiparametric flow (n = 20) mass cytometry ( n 21) human tumors. Transcriptome data from tumors 351) profiled by The Cancer Genome Atlas (TCGA)...
Despite its immunogenic nature, bladder cancer (BCa) responds sub-optimally to FDA-approved immunotherapy. Background/Objectives: We have previously shown that natural killer (NK) cells are major contributors overall patient survival in BCa. In our efforts identify clinically approved agents enhance NK cell activation, we identified eribulin, a microtubule destabilizer primarily used breast cancer. Ongoing clinical trials investigating the potential integration of eribulin into standard care...
Aging is tightly associated with reduced immune protection but increased risk of autoimmunity and inflammatory conditions. Regulatory T cells are one the key to maintaining homeostasis. The age-dependent changes in CD4
Abstract Purpose Human innate lymphoid cells (hILCs) are lineage‐negative immune that do not express rearranged adaptive antigen receptors. Natural killer (NK) hILCs contribute to cancer defense. The role of non‐NK in is unclear. Our study aimed characterize bladder cancer. Experimental design Mass cytometry was used intratumoral based on 35 parameters, including receptors, cytokines, and transcription factors from 21 muscle‐invasive tumors. Model‐based clustering performed t‐distributed...